| Recruiting | STOP-HAE: A Phase 3 Study of ADX-324 in HAE NCT06960213 | ADARx Pharmaceuticals, Inc. | Phase 3 |
| Completed | A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks NCT07009262 | KalVista Pharmaceuticals, Ltd. | — |
| Recruiting | Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab NCT06806657 | CSL Behring | Phase 4 |
| Active Not Recruiting | HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) NCT06634420 | Intellia Therapeutics | Phase 3 |
| Recruiting | Institutional Registry of Rare Diseases NCT06573723 | Hospital Italiano de Buenos Aires | — |
| Completed | Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE NCT06467084 | KalVista Pharmaceuticals, Ltd. | Phase 3 |
| Enrolling By Invitation | Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 NCT06262399 | Intellia Therapeutics | — |
| Completed | Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adul NCT06343779 | Pharvaris Netherlands B.V. | Phase 3 |
| Active Not Recruiting | A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema NCT06007677 | Astria Therapeutics, Inc. | Phase 2 |
| Completed | Autonomic Nervous System Profile in Hereditary Angioedema NCT06408805 | Istituti Clinici Scientifici Maugeri SpA | — |
| Completed | Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients NCT06414252 | Istituti Clinici Scientifici Maugeri SpA | — |
| Completed | A Study of STAR-0215 in Participants With Hereditary Angioedema NCT05695248 | Astria Therapeutics, Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angio NCT05396105 | Pharvaris Netherlands B.V. | Phase 2 / Phase 3 |
| Active Not Recruiting | Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients NCT05691361 | ADARx Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Berotralstat Treatment in Children With Hereditary Angioedema NCT05453968 | BioCryst Pharmaceuticals | Phase 3 |
| Active Not Recruiting | An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatmen NCT05505916 | KalVista Pharmaceuticals, Ltd. | Phase 3 |
| Active Not Recruiting | PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial NCT05511922 | KalVista Pharmaceuticals, Ltd. | Phase 3 |
| Completed | A Study of STAR-0215 in Healthy Adult Participants NCT05477160 | Astria Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditar NCT05392114 | Ionis Pharmaceuticals, Inc. | Phase 3 |
| Completed | A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary Angioedema NCT04957641 | Takeda | — |
| Completed | Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary A NCT05047185 | Pharvaris Netherlands B.V. | Phase 2 |
| Completed | A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatme NCT05259917 | KalVista Pharmaceuticals, Ltd. | Phase 3 |
| Active Not Recruiting | A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema NCT05121376 | BioMarin Pharmaceutical | Phase 1 / Phase 2 |
| Active Not Recruiting | NTLA-2002 in Adults With Hereditary Angioedema (HAE) NCT05120830 | Intellia Therapeutics | Phase 1 / Phase 2 |
| Completed | OASIS-HAE: A Study to Evaluate the Safety and Efficacy of Donidalorsen (ISIS 721744 or IONIS-PKK-LRx) in Parti NCT05139810 | Ionis Pharmaceuticals, Inc. | Phase 3 |
| Withdrawn | Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema NCT04898309 | AO GENERIUM | Phase 2 / Phase 3 |
| Enrolling By Invitation | Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies NCT04933721 | BioCryst Pharmaceuticals | Phase 3 |
| Completed | Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema NCT04888650 | University Hospital, Grenoble | — |
| Completed | Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema A NCT04739059 | CSL Behring | Phase 3 |
| Completed | Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema NCT04687137 | Takeda | Phase 3 |
| Completed | Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary An NCT04618211 | Pharvaris Netherlands B.V. | Phase 2 |
| Completed | CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks NCT04656418 | CSL Behring | Phase 3 |
| Completed | A Study of Icatibant (TAK-667) in Japanese Children and Teenagers With Acute Attacks of Hereditary Angioedema NCT04654351 | Takeda | Phase 3 |
| Completed | Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple NCT05118958 | KalVista Pharmaceuticals, Ltd. | Phase 1 |
| Completed | An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema NCT04307381 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Completed | Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers NCT04557319 | AO GENERIUM | Phase 1 |
| Completed | A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Parti NCT04030598 | Ionis Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Hereditary Angioedema Kininogen Assay NCT04091113 | CENTOGENE GmbH Rostock | — |
| Completed | A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children NCT04070326 | Shire | Phase 3 |
| Completed | A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-de NCT04208412 | KalVista Pharmaceuticals, Ltd. | Phase 2 |
| Completed | A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy NCT05178355 | KalVista Pharmaceuticals, Ltd. | Phase 1 |
| Completed | A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) NCT03712228 | CSL Behring | Phase 2 |
| Completed | Biomarker for Hereditary AngioEdema Disease NCT03029728 | CENTOGENE GmbH Rostock | — |
| Completed | Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest) NCT06690047 | Bernstein Clinical Research Center | Phase 4 |
| Completed | Patient Registry to Evaluate the Real-world Safety of Ruconest® NCT03697187 | Pharming Technologies B.V. | — |
| Completed | A Long Term Safety Study of BCX7353 in Hereditary Angioedema NCT03472040 | BioCryst Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE NCT03485911 | BioCryst Pharmaceuticals | Phase 3 |
| Completed | A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy NCT04349800 | KalVista Pharmaceuticals, Ltd. | Phase 1 |
| Completed | A Relative Bioavailability Study of Two Formulations of BCX7353 NCT03202784 | BioCryst Pharmaceuticals | Phase 1 |
| Completed | A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions NCT03136237 | BioCryst Pharmaceuticals | Phase 1 |
| Completed | An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity NCT02819102 | BioCryst Pharmaceuticals | Phase 1 |
| Terminated | Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population NCT02854397 | University Hospital, Grenoble | — |
| Terminated | Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema NCT02670720 | BioCryst Pharmaceuticals | Phase 3 |
| Completed | First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in NCT02448264 | BioCryst Pharmaceuticals | Phase 1 |
| Completed | 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks NCT02303626 | BioCryst Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor NCT02247739 | Pharming Technologies B.V. | Phase 2 |
| Unknown | Hereditary AngioEdema, Neurobiology and Psychopathology NCT02159430 | University Hospital, Catania | — |
| Completed | Study to Determine How BCX4161 is Metabolized and Eliminated by the Body NCT02218294 | BioCryst Pharmaceuticals | Phase 1 |
| Completed | A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 NCT02125162 | BioCryst Pharmaceuticals | Phase 1 |
| Completed | Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE NCT01984788 | BioCryst Pharmaceuticals | Phase 2 |
| Completed | A Call Center During HAE Attacks (SOS HAE) NCT01679912 | Assistance Publique - Hôpitaux de Paris | Phase 4 |
| Completed | Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients NCT01359969 | Pharming Technologies B.V. | Phase 2 |
| Completed | Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE NCT01457430 | Massachusetts General Hospital | Phase 4 |
| Completed | A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Hum NCT01426763 | Shire | Phase 2 |
| Completed | C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks NCT01397864 | Pharming Technologies B.V. | — |
| Completed | Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Att NCT01188564 | Pharming Technologies B.V. | Phase 3 |
| Withdrawn | C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation NCT01151735 | Penn State University | Phase 4 |
| Completed | A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration NCT01095497 | Shire | Phase 2 |
| Completed | EASSI - Evaluation of the Safety of Self-Administration With Icatibant NCT00997204 | Shire | Phase 3 |
| Completed | A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE NCT00914966 | Shire | Phase 4 |
| Completed | A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3) NCT00912093 | Shire | Phase 3 |
| Completed | A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration NCT00851409 | Pharming Technologies B.V. | Phase 2 |
| Completed | Berinert P Study of Subcutaneous Versus Intravenous Administration NCT00748202 | Johann Wolfgang Goethe University Hospital | Phase 3 |
| Completed | Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects NCT00432510 | Shire | Phase 1 |
| Completed | Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks NCT00438815 | Shire | Phase 3 |
| Completed | Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks NCT00462709 | Shire | Phase 3 |
| Completed | C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) NCT00292981 | CSL Behring | Phase 3 |
| Completed | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema NCT00225147 | Pharming Technologies B.V. | Phase 2 / Phase 3 |
| Completed | Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) At NCT00168103 | CSL Behring | Phase 2 / Phase 3 |
| Completed | C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks NCT01005888 | Shire | Phase 3 |
| Completed | C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks NCT00289211 | Shire | Phase 3 |
| Completed | Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) NCT00500656 | Shire | Phase 3 |
| Completed | Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema NCT00262301 | Pharming Technologies B.V. | Phase 3 |
| Approved For Marketing | Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With NCT06628713 | KalVista Pharmaceuticals, Ltd. | — |
| Available | Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetrals NCT07216378 | KalVista Pharmaceuticals, Ltd. | — |
| Approved For Marketing | Oral Berotralstat Expanded Access Program NCT04428632 | BioCryst Pharmaceuticals | — |
| Available | Donidalorsen Expanded Access Program for Patients With Hereditary Angioedema NCT06415448 | Ionis Pharmaceuticals, Inc. | — |